Richard Levick was recently quoted in the Wall Street Journal on Mylan’s handling of the EpiPen crisis:
“It’s not good when a corporate crisis gets its own hashtag and thousands of people begin using it. It’s even worse when that hashtag ends in ‘gate.’ Yet Mylan’s handling of its EpiPen pricing issue—#Epigate as it was tagged by one parent/activist—is hardly scandalous. In truth, once it became a news story three days after #Epigate was coined, Mylan deserves reasonably high marks for its response. Its messaging and strategy were solid. It offered a discounted purchasing plan. It took the dramatic step of developing a generic alternative to make EpiPen more affordable. Its chief executive assumed public responsibility and made herself accessible to the media.”
